Xtl Biopharmaceuticals Ltd Stock Today
| XTLB Stock | USD 1.88 0.05 2.73% |
Performance0 of 100
| Odds Of DistressOver 81
|
XTL Biopharmaceutica is trading at 1.88 as of the 26th of November 2024, a 2.73% increase since the beginning of the trading day. The stock's open price was 1.83. XTL Biopharmaceutica has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Equity ratings for XTL Biopharmaceuticals Ltd are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 5th of July 2023 and ending today, the 26th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 1st of September 2005 | Category Healthcare | Classification Health Care |
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel. The company has 5.45 M outstanding shares of which 213.42 K shares are at this time shorted by private and institutional investors with about 2.39 trading days to cover. More on XTL Biopharmaceuticals Ltd
Moving together with XTL Stock
| 0.64 | A | Agilent Technologies | PairCorr |
| 0.77 | ME | 23Andme Holding | PairCorr |
| 0.75 | VALN | Valneva SE ADR | PairCorr |
| 0.65 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
Moving against XTL Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
XTL Stock Highlights
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, NASDAQ Composite Total, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsXTL Biopharmaceutica can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand XTL Biopharmaceutica's financial leverage. It provides some insight into what part of XTL Biopharmaceutica's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
XTL Biopharmaceuticals Ltd (XTLB) is traded on NASDAQ Exchange in USA. It is located in 26 Ben-Gurion St., Ramat Gan, Israel, 5112001 and employs 4 people. XTL Biopharmaceutica is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 10.24 M. XTL Biopharmaceuticals conducts business under Biotechnology sector and is part of Health Care industry. The entity has 5.45 M outstanding shares of which 213.42 K shares are at this time shorted by private and institutional investors with about 2.39 trading days to cover.
XTL Biopharmaceuticals Ltd currently holds about 5.16 M in cash with (707 K) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.95.
Check XTL Biopharmaceutica Probability Of Bankruptcy
Ownership AllocationThe market capitalization of XTL Biopharmaceuticals is $10.24 Million. XTL Biopharmaceuticals maintains 5.0 (%) of its outstanding shares held by insiders and 1.92 (%) owned by institutional investors. Note, that even with negative profits, if the true value of the company is larger than the current market value, you may still be able to generate positive returns on investment in this company.
Check XTL Ownership Details
XTL Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Noked Israel Ltd | 2024-06-30 | 198.9 K | |
| Morgan Stanley - Brokerage Accounts | 2024-06-30 | 66.3 K | |
| Rhumbline Advisers | 2024-06-30 | 5.6 K | |
| Bnp Paribas Arbitrage, Sa | 2024-06-30 | 0.0 | |
| Ubs Group Ag | 2024-06-30 | 0.0 | |
| Citadel Advisors Llc | 2024-09-30 | 0.0 |
XTL Biopharmaceutica Historical Income Statement
XTL Stock Against Markets
XTL Biopharmaceutica Corporate Management
| Itay CPA | Chief Officer | Profile | |
| Itay Weinstein | Chief Officer | Profile | |
| Shlomo Shalev | CEO Director | Profile | |
| Ronen Kantor | Company Sec | Profile |
Already Invested in XTL Biopharmaceuticals Ltd?
The danger of trading XTL Biopharmaceuticals Ltd is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of XTL Biopharmaceutica is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than XTL Biopharmaceutica. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile XTL Biopharmaceuticals is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether XTL Biopharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of XTL Biopharmaceutica's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Xtl Biopharmaceuticals Ltd Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Xtl Biopharmaceuticals Ltd Stock: Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in XTL Biopharmaceuticals Ltd. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of XTL Biopharmaceutica. If investors know XTL will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about XTL Biopharmaceutica listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.76) | Earnings Share (0.03) | Return On Assets (0.14) | Return On Equity (0.13) |
The market value of XTL Biopharmaceuticals is measured differently than its book value, which is the value of XTL that is recorded on the company's balance sheet. Investors also form their own opinion of XTL Biopharmaceutica's value that differs from its market value or its book value, called intrinsic value, which is XTL Biopharmaceutica's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because XTL Biopharmaceutica's market value can be influenced by many factors that don't directly affect XTL Biopharmaceutica's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between XTL Biopharmaceutica's value and its price as these two are different measures arrived at by different means. Investors typically determine if XTL Biopharmaceutica is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, XTL Biopharmaceutica's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.